Cristina Represas-Represas1,2, Luz Aballe-Santos1,2, Alberto Fernández-García2, Ana Priegue-Carrera1,2, José-Luis López-Campos3,4, Almudena González-Montaos1,2, Maribel Botana-Rial1,2, Alberto Fernández-Villar1,2. 1. Pneumology Department, Alvaro Cunqueiro University Hospital, 36312 Vigo, Spain. 2. NeumoVigo I+i Research Group, Institute of Health Research Galicia Sur (IISGS, Instituto de Investigación Sanitaria Galicia Sur), 36312 Vigo, Spain. 3. Medical-Surgical Unit of Respiratory Diseases, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/University of Seville, 41013 Seville, Spain. 4. Centre for Biomedical Research in Respiratory Diseases Network (CIBERES), Institute of Health Carlos III, 28029 Madrid, Spain.
Abstract
OBJECTIVE: Although the importance of assessing inspiratory flow in the selection of treatments for chronic obstructive pulmonary disease (COPD) is understood, evaluation of this factor is not yet widespread or standardized. The objective of the present work was to evaluate the peak inspiratory flow (PIF) of patients with COPD and to explore the variables associated with a suboptimal PIF. METHODS: An observational, cross-sectional study was carried out at specialized nursing consultations over a period of 6 months. We collected clinical data as well as data on symptoms, treatment adherence, and patient satisfaction with their inhalers via questionnaires. PIF was determined using the In-Check Dial G16® device (Clement Clarke International, Ltd., Harlow, UK). In each case, the PIF was considered suboptimal when it was off-target for any of the prescribed inhalers. The association with suboptimal PIF was evaluated using multivariate logistic regression and the results were expressed as the odds ratio (OR) with 95% confidence interval (CI). RESULTS: A total of 122 COPD patients were included in this study, of whom 34 (27.9%) had suboptimal PIF. A total of 229 inhalers were tested, of which 186 (81.2%) were dry powder devices. The multivariate analysis found an association between suboptimal PIF and age (OR = 1.072; 95% CI (1.019, 1.128); p = 0.007) and forced vital capacity (OR = 0.961; 95% CI (0.933, 0.989); p = 0.006). CONCLUSIONS: About a third of patients in complex specialized COPD care have suboptimal PIFs, which is related to age and forced vital capacity.
OBJECTIVE: Although the importance of assessing inspiratory flow in the selection of treatments for chronic obstructive pulmonary disease (COPD) is understood, evaluation of this factor is not yet widespread or standardized. The objective of the present work was to evaluate the peak inspiratory flow (PIF) of patients with COPD and to explore the variables associated with a suboptimal PIF. METHODS: An observational, cross-sectional study was carried out at specialized nursing consultations over a period of 6 months. We collected clinical data as well as data on symptoms, treatment adherence, and patient satisfaction with their inhalers via questionnaires. PIF was determined using the In-Check Dial G16® device (Clement Clarke International, Ltd., Harlow, UK). In each case, the PIF was considered suboptimal when it was off-target for any of the prescribed inhalers. The association with suboptimal PIF was evaluated using multivariate logistic regression and the results were expressed as the odds ratio (OR) with 95% confidence interval (CI). RESULTS: A total of 122 COPDpatients were included in this study, of whom 34 (27.9%) had suboptimal PIF. A total of 229 inhalers were tested, of which 186 (81.2%) were dry powder devices. The multivariate analysis found an association between suboptimal PIF and age (OR = 1.072; 95% CI (1.019, 1.128); p = 0.007) and forced vital capacity (OR = 0.961; 95% CI (0.933, 0.989); p = 0.006). CONCLUSIONS: About a third of patients in complex specialized COPD care have suboptimal PIFs, which is related to age and forced vital capacity.
Authors: Vicente Plaza; Concepción Fernández-Rodríguez; Carlos Melero; Borja G Cosío; Luís Manuel Entrenas; Luis Pérez de Llano; Fernando Gutiérrez-Pereyra; Eduard Tarragona; Rosa Palomino; Antolín López-Viña Journal: J Aerosol Med Pulm Drug Deliv Date: 2015-07-31 Impact factor: 2.849
Authors: Walter Sepúlveda-Loyola; Christian Osadnik; Steven Phu; Andrea A Morita; Gustavo Duque; Vanessa S Probst Journal: J Cachexia Sarcopenia Muscle Date: 2020-08-30 Impact factor: 12.910
Authors: Brendan Clark; Brian J Wells; Amit K Saha; Jessica Franchino-Elder; Asif Shaikh; Bonnie M K Donato; Jill A Ohar Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-06-29
Authors: Jill A Ohar; Gary T Ferguson; Donald A Mahler; M Bradley Drummond; Rajiv Dhand; Roy A Pleasants; Antonio Anzueto; David M G Halpin; David B Price; Gail S Drescher; Haley M Hoy; John Haughney; Michael W Hess; Omar S Usmani Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-01-06
Authors: Donald A Mahler; Andrea Ludwig-Sengpiel; Gary T Ferguson; Alberto de la Hoz; John Ritz; Asif Shaikh; Henrik Watz Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-08-28